Intravenous immunoglobulin therapy for Miller Fisher syndrome
- 3 April 2007
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 68 (14), 1144-1146
- https://doi.org/10.1212/01.wnl.0000258673.31824.61
Abstract
We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.This publication has 8 references indexed in Scilit:
- Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody bindingBrain, 2003
- Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive casesJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Clinical features and prognosis of Miller Fisher syndromeNeurology, 2001
- Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndromeNeurology, 1996
- The use of intravenous immunoglobulin in Miller Fisher syndromeBrain & Development, 1993
- A Randomized Trial Comparing Intravenous Immune Globulin and Plasma Exchange in Guillain–Barré SyndromeThe New England Journal of Medicine, 1992
- Plasmapheresis and acute Guillain‐Barre syndromeNeurology, 1985
- An Unusual Variant of Acute Idiopathic Polyneuritis (Syndrome of Ophthalmoplegia, Ataxia and Areflexia)The New England Journal of Medicine, 1956